|
|
 |
|
 |
| Home | About and More Information | Transporter Data Index |
Synonyms: P, P-, Evi, Mdr, Pgp, Pgy, Mdr3, P-gp, Pgy-, Pgy3, mdr-, Abcb4, Evi32, Mdr1a, Pgy-3, mdr-3
Entrez Gene Link
No expression data.
No substrate information.
| Inhibitor | IC50 (μM) | Ki (μM) | Substrate used | Cell System | Reference |
|---|---|---|---|---|---|
| Aldrin | 26.2 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Alpha-hexachlorocyclohexane | 26.8 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Astemizole | 1.3 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Cimetidine | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Clotrimazole | 4.8 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Colchicine | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Cyclosporine | 4.8 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Dexamethasone | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Dieldrin | 21.8 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Digoxin | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| DPDE (enkephalin) | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Endrin | 1.1 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Erythromycin | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Etoposide | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Gamma-hexachlorocyclohexane | 82.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Heptachlor | 10.4 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Hydrocortisone | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Itraconazole | 0.2 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Ivermectin | 0.5 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Ivermectin | 0.4 | Rhodamine 123 | LLC-PK1 cells | Lespine, 2006 | |
| Ketoconazole | 3.8 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Methoxychlor (nonspecific) | 21.7 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Mibefradil | 7.4 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Miconazole | 7.8 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Midazolam | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Mirex | 3 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Morphine | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Nelfinavir | 2.3 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Nicardipine | 2.5 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| PBDE-100 | 23.2 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PBDE-209 | 6.5 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PBDE-47 | 22.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PBDE-49 | 35.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-118 | 15.9 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-134 | 12.5 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-142 | 6.1 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-145 | 4.4 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-146 | 12.8 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-147 | 23.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-152 | 22 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-153 | 21.8 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-154 | 14.3 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-161 | 43.2 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-168 | 25.8 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-169 | 9.7 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-170 | 9.2 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-186 | 6.9 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| PCB-187 | 11.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Perfluorooctanoic acid | 156.5 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Pimozide | 4.9 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| p,p'-DDD | 72.5 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| p,p'-DDE | 31.3 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| p,p'-DDT | 25.6 | Verapamil | Purified, detergent-solubilized protein | Nicklisch, 2016 | |
| Quinidine | 13 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Ranitidine | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Ritonavir | 50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Saquinavir | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Terfenadine | 23 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Verapamil | 10 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 | |
| Vinblastine | >50 | Calcein AM | Mouse mdr1a expressing LLC-PK1 cells | Schwab, 2003 |
ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022
No drug-drug interaction information.
 |